Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infrastructure development for human cell therapy translation.

A B Dietz1, D J Padley, D A Gastineau

  • 1Human Cellular Therapy Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dietz.Allan@mayo.edu

Clinical Pharmacology and Therapeutics
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Bone marrow transplantation·2017
Same author

Autologous stem cell transplant for multiple myeloma patients 70 years or older.

Bone marrow transplantation·2016
Same author

A novel intranuclear RNA vector system for long-term stem cell modification.

Gene therapy·2015
Same author

IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.

Blood cancer journal·2015
Same author

Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.

Bone marrow transplantation·2013
Same author

Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT.

Bone marrow transplantation·2013

Cell therapy utilizes cells as medicinal products, building on decades of use. Establishing robust infrastructure and quality control is crucial for the safe and effective development of these cellular therapies in clinical trials.

Area of Science:

  • Cellular therapy
  • Biotechnology
  • Regenerative medicine

Background:

  • Cells have historically been used therapeutically, with early examples including tissue transplantation like bone marrow.
  • The concept of cells as drugs has evolved, with a growing focus on their specific therapeutic effects.

Purpose of the Study:

  • To explore the regulatory landscape and practical design considerations for manufacturing infrastructure supporting cell therapy development.
  • To highlight the critical role of infrastructure in ensuring the safety, potency, and regulatory compliance of cell therapy products, especially for early clinical trials.

Main Methods:

  • Review of historical cell transplantation practices and lessons learned from blood banking.
  • Analysis of the regulatory environment impacting cell therapy manufacturing.

Related Experiment Videos

  • Discussion of practical design considerations for manufacturing facilities.

    • Main Results:

    • Quality control, process control, sterility, and product tracking are essential for cell therapy safety and potency, drawing parallels with blood banking.
    • Development of specialized infrastructure is necessary to support the increasing exploitation of cells as drugs.
    • Facility design must consider capital investment and its role in regulatory compliance.

    Conclusions:

    • Cellular therapies represent a critical advancement in medicine, requiring specialized infrastructure and stringent quality control.
    • The successful translation of cell therapies from research to clinical application hinges on careful planning of manufacturing facilities and adherence to regulatory guidelines.